OUTLOOK THERAPEUTICS, INC. Stock Nasdaq
Stocks
US68235M1053
Biotechnology & Medical Research
| Market Cap | 211M 183M 171M 156M 294M 20.15B 299M 2.01B 788M 10.09B 793M 776M 33.65B | P/E 2026 * |
-2.38x | P/E 2027 * | -5.84x |
|---|---|---|---|---|---|
| Enterprise Value | 211M 183M 171M 156M 294M 20.15B 299M 2.01B 788M 10.09B 793M 776M 33.65B | EV / Sales 2026 * |
51.3x | EV / Sales 2027 * | 3.64x |
| Free-Float |
85.03% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: OUTLOOK THERAPEUTICS, INC.
| 1 day | -0.09% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Jahr
CEO | Chief Executive Officer | 54 | 2025-06-30 |
Lawrence Kenyon
CEO | Chief Executive Officer | 60 | 2024-12-02 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 2023-01-18 |
| Director | Title | Age | Since |
|---|---|---|---|
Lawrence Kenyon
BRD | Director/Board Member | 60 | 2018-08-01 |
Kurt Hilzinger
BRD | Director/Board Member | 65 | 2015-12-10 |
| Chairman | 41 | 2025-01-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.09% | +11.48% | - | - | 211M | |
| -1.70% | +0.71% | +3.55% | +14.41% | 49.54B | |
| -0.69% | +6.25% | +492.36% | +585.40% | 44.06B | |
| +0.08% | +11.23% | +23.99% | +81.74% | 40.85B | |
| +0.76% | +6.85% | +35.40% | +10.92% | 40.14B | |
| +4.73% | +13.29% | +27.76% | +54.22% | 34.17B | |
| +0.51% | +5.29% | +34.62% | +126.87% | 16.9B | |
| -0.41% | +4.08% | - | - | 16.78B | |
| -0.37% | -0.03% | +4.28% | +20.78% | 14B | |
| +1.81% | +20.45% | +89.35% | +31.49% | 13.46B | |
| Average | +0.46% | +7.75% | +88.92% | +115.73% | 29.99B | |
| Weighted average by Cap. | +0.37% | +7.39% | +106.93% | +138.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.12M 3.57M 3.34M 3.05M 5.74M 393M 5.84M 39.21M 15.36M 197M 15.48M 15.14M 657M | 58M 50.26M 47.05M 42.93M 80.79M 5.53B 82.15M 552M 216M 2.77B 218M 213M 9.24B |
| Net income | -47.92M -41.53M -38.88M -35.47M -66.75M -4.57B -67.88M -456M -179M -2.29B -180M -176M -7.63B | -32.34M -28.03M -26.24M -23.94M -45.05M -3.08B -45.81M -308M -121M -1.54B -121M -119M -5.15B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
